Sector News

MedImmune, Abpro create new firm

November 30, 2016
Life sciences

AstraZeneca’s biologics research and development arm MedImmune and US life sciences group Abpro have spun out a new company to advance development of a preclinical, novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF).

Abpro will oversee day-to-day leadership of the new group, AbMed, which will explore several potential therapeutic areas where inhibition of the Ang2 and VEGF pathways with this unique bispecific antibody may provide clinical benefit.

The antibody, which was engineered by scientists at MedImmune, has demonstrated potent activity in animal models, which may be useful in targeting disease indications with high unmet needs, the firms note.

Abpro will use its scientific, technical and clinical expertise to drive forward the new firm and its technology platform, DiversImmune, to further refine the antibody.

Under the terms of the deal, AbMed, which will operate as a subsidiary of Abpro, will receive majority global development and commercialisation rights to the program, and MedImmune development, regulatory and sales milestones and royalties, as well as hold a minority equity stake in AbMed.

“This agreement arises out of MedImmune’s culture of entrepreneurship and innovation — both in science and in business,” said Jane Osbourn, vice president of R&D at MedImmune. “We believe partners like Abpro can help us maximise our extensive pre-clinical portfolio to advance therapies for patients.”

By Selina McKee

Source: Pharma Times

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach